-+ 0.00%
-+ 0.00%
-+ 0.00%

US Court Denies Novo Nordisk's Bid to Block Eli Lilly's Ads Targeting Wegovy, Ozempic

MT Newswires·10/27/2026 06:18:40
Listen to the news
06:18 AM EDT, 10/27/2026 (MT Newswires) -- A US federal court in New Jersey denied Novo Nordisk's (NOVO-B.CO) motion for a preliminary injunction against Eli Lilly's (LLY.SW, LLY.F) advertisements, which claim its drugs are stronger than the Danish drugmaker's. In a 25-page opinion published Monday, US District Judge Zahid Quraishi said Novo's claims that Lilly's ads are causing lasting damage to its clinical reputation offer only "speculative claims of harm." He added that Novo has asserted, with no cited or submitted evidence, that the ads threaten future sales and have harmed the goodwill it cultivated over the years. Novo filed the lawsuit in July based on Lilly's Mounjaro and Zepbound advertisements, which compare those drugs with Wegovy and Ozempic. The drugmakers did not immediately respond to requests for comment from MT Newswires.